Galapagos NV : Galapagos discovers novel candidate drug to treat breast cancer

Galapagos NV : Galapagos discovers novel candidate drug to treat breast cancer

  oGLPG1790 has high efficacy against triple-negative breast cancer
  oInnovative, targeted approach
  oGalapagos plans to initiate clinical trials within one year

Mechelen, Belgium; 22  April 2013  - Galapagos NV  (Euronext: GLPG)  announced 
today that  it developed  GLPG1790, a  novel candidate  drug to  treat  breast 
cancer. GLPG1790  has shown  high  activity against  breast tumors  that  are 
triple-negative, for which the absence of estrogen (ER), progesterone (PR)  or 
HER2 receptors affects the prognosis for recovery, and no targeted therapeutic
options are currently available. 

Breast cancer is a disease in which tumor cells form in the breast tissue;  it 
is one of the most common types of cancer in women. There are many  different 
types of  breast  cancer,  and  as  a  result,  there  are  many  options  for 
treatment.   Targeted    drug   treatments    such   as    Herceptin^®    and 
Avastin^®^[1]attack specific types of  breast cancer cells. Decisions  about 
the best possible  treatment with targeted  drugs are based  on tests for  the 
presence of ER, PR and  HER2^[2]. Triple-negative breast cancer (tumor  cells 
that have no ER, PR and HER2) accounts for one-fifth of breast cancers, and it
usually affects  young  women. There  are  no targeted  drugs  available  for 
patients with triple-negative breast cancer.

Candidate drug GLPG1790 is a selective and potent inhibitor of a novel  breast 
cancer target;  the candidate  drug has  proven to  be highly  active  against 
triple-negative breast cancer in a  mouse xenograft model where it  completely 
blocks  tumor   growth.  GLPG1790   has   good  drug-like   properties,   and 
safety/tolerability studies with the candidate drug look favorable. Galapagos
will initiate preclinical studies with  GLPG1790, and expects to initiate  the 
first clinical trials in humans within one year. This novel program is  fully 
proprietary to Galapagos.

"GLPG1790 is the result of a multi-year research program on a novel  mechanism 
of action  discovered  with  our  target discovery  platform,"  says  Dr  Piet 
Wigerinck, Galapagos  CSO.  "We  are  pleased to  have  developed  a  targeted 
approach towards  triple-negative  breast  cancer.  Targeted  approaches  in 
oncology typically show good efficacy and less toxicity than  chemotherapy." 


About Galapagos
Galapagos   (Euronext:   GLPG;   OTC:   GLPYY)   is   specialized   in   novel 
modes-of-action, with a large pipeline  of four clinical, seven  pre-clinical, 
and 30  discovery small-molecule  and antibody  programs in  cystic  fibrosis, 
inflammation, antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment
of rheumatoid arthritis and potentially other inflammatory diseases, about  to 
enter Phase  2b studies.  AbbVie  and Galapagos  signed a  worldwide  license 
agreement whereby  AbbVie  will be  responsible  for further  development  and 
commercialization after  Phase  2b.  Galapagos  has  another  selective  JAK1 
inhibitor in Phase 2  in lupus and  psoriasis, GSK2586184 (formerly  GLPG0778, 
in-licensed by  GlaxoSmithKline  in  2012).  GLPG0187  is  a  novel  integrin 
receptor antagonist  currently in  a Phase  1b patient  study in  metastasis. 
GLPG0974 is the  first inhibitor of  FFA2 to be  evaluated clinically for  the 
treatment of IBD; this  program will start  a Proof of  Concept Phase 2  study 
this quarter.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has over  800 employees  and operates facilities  in five  countries, 
with global  headquarters  in  Mechelen,  Belgium.  Further  information  at: 
www.glpg.com

CONTACT

Galapagos NV
Dr Piet Wigerinck, Chief Scientific Officer
Tel. +32 477 627103

Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com

This  release  may  contain  forward-looking  statements,  including,  without 
limitation,  statements  containing   the  words  "believes,"   "anticipates," 
"expects," "intends," "plans," "seeks,"  "estimates," "may," "will,"  "could," 
"stands  to,"  and   "continues,"  as  well   as  similar  expressions.   Such 
forward-looking statements may involve known and unknown risks,  uncertainties 
and other factors which might  cause the actual results, financial  condition, 
performance  or  achievements  of  Galapagos,  or  industry  results,  to   be 
materially  different  from   any  historic  or   future  results,   financial 
conditions,  performance  or  achievements   expressed  or  implied  by   such 
forward-looking statements. Given these  uncertainties, the reader is  advised 
not to  place any  undue reliance  on such  forward-looking statements.  These 
forward-looking statements speak only  as of the date  of publication of  this 
document. Galapagos  expressly disclaims  any obligation  to update  any  such 
forward-looking statements  in this  document  to reflect  any change  in  its 
expectations with  regard  thereto or  any  change in  events,  conditions  or 
circumstances on which any such statement is based, unless required by law  or 
regulation.

-------------------------

[1]Herceptin^® and Avastin^® are registered trademarks of Roche for
trastuzumab and bevacizumab, respectively

[2]Human epidermal growth factor type 2 receptor



------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Galapagos NV via Thomson Reuters ONE
HUG#1694682
 
Press spacebar to pause and continue. Press esc to stop.